Andrew Huberman· PhD
And I have great optimism for this business of clinical use of psychedelics, including MDMA. Matthew Johnson at Johns Hopkins is doing fabulous work on this.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
And I have great optimism for this business of clinical use of psychedelics, including MDMA. Matthew Johnson at Johns Hopkins is doing fabulous work on this.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
I see very few people inside the halls of academia who have thrown their arms around this issue of psychedelics in a way, and gone through the trouble of trying to find the funding to get it done, gone through the trouble of trying to set up clinical trials.